Bicara Therapeutics Inc. Common Stock (BCAX)
PHARMACEUTICAL PREPARATIONS
Bicara Therapeutics Inc. Common Stock (BCAX) is listed on Nasdaq, where it has traded since September 13, 2024.
- Listed On
- Nasdaq
- Listed Since
- September 13, 2024
- Employees
- 103
- Market Cap
- $646M
About Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 164 institutions reported holding BCAX, with 69.8 million shares worth $2.1 billion in aggregate. The largest reported holder was T. Rowe Price, with 8.2 million shares worth $244.7 million. Of the 5 largest holders listed below, 2 added shares, 2 reduced their positions and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| T. Rowe Price | 8,242,735 | $245M | Added 3.27% |
| RA Capital Management | 7,255,993 | $215M | Unchanged |
| Siren | 5,602,970 | $166M | Reduced 3.45% |
| Vestal Point Capital | 5,250,000 | $156M | Reduced 3.23% |
| Deep Track Capital | 4,100,000 | $122M | Added 0.92% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is BCAX?
Bicara Therapeutics Inc. Common Stock (BCAX) is listed on Nasdaq, where it has traded since September 13, 2024.
Who are the largest institutional holders of BCAX?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of BCAX were T. Rowe Price, RA Capital Management and Siren.
How many institutions own BCAX?
164 institutions reported a position in BCAX for the quarter ended June 30, 2026, worth $2.1 billion in total.
Did institutions buy or sell BCAX last quarter?
Of the 5 largest reported holders, 2 added shares, 2 reduced their positions and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for BCAX.
Every reported institutional holder, plus insider and congressional trades in BCAX, on SentiSense.